April 1, 2008 - "CCTA may be used as a cost-efficient alternative to nuclear stress testing for evaluation of patients with suspected coronary artery disease,"? said James Min, M.D., New York-Presbyterian Hospital and Weill Medical College of Cornell University, NY, at at the American College of Cardiology (ACC) meeting in Chicago, IL. The report concluded 64-slice coronary CT angiography (CCTA) is more cost-effective in patients without a prior coronary artery disease (CAD) diagnosis, while SPECT myocardial perfusion imaging retains a cost advantage in patients with known coronary artery disease. In the study, researchers examined claims from health plans covering more than 10 million individuals, using ICD-9 codes to identify 142,535 patients with suspected CAD who underwent either coronary CTA or SPECT. Data was matched to 2,313 patients undergoing CTA, and 9,252 undergoing SPECT imaging (for both exams mean age 53, 41.5 percent female, 10.6 percent with diabetes mellitus, 40 percent hypertension, 52.5 percent hyperlipidemia, 16.2 percent known CAD), and five other risk factors. Patient costs and outcomes were tracked for Over nine months before and after the exam, researchers tracked patient costs and outcomes, and assessed cardiac risk based on each patient's risk factors and medications. Investigators then calculated the costs of the disease after both tests, and recorded adverse events, including myocardial infarction, angina and hospitalizations related to coronary artery disease. After multivariate adjustment, the downstream costs of coronary artery disease for patients without a prior CAD diagnosis were lower in CTA patients by $603 (95 percent confidence index [CI] $244-$2,053, p < 0.001) compared to the SPECT group. For the 16.2 percent of patients with known CAD, however, costs were lower in the SPECT group by $2,451 (95 percent CI $1,474-$4,068, p < 0.001) compared to CTA. There were no significant differences between CTA and SPECT in myocardial infarction rates (0.7 percent versus 0.8 percent), incident angina (3.8 percent versus 4.0 percent), or CAD-related hospitalizations (0.2 percent vs. 0.2 percent), according to the report. For more information: www.acc08.org
CCTA Offers Cost-Efficient Alternative to SPECT in CAD
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.